Nothing Special   »   [go: up one dir, main page]

Arévalo et al., 2004 - Google Patents

A unique pathway for sustained neurotrophin signaling through an ankyrin‐rich membrane‐spanning protein

Arévalo et al., 2004

View PDF
Document ID
10614183023156715818
Author
Arévalo J
Yano H
Teng K
Chao M
Publication year
Publication venue
The EMBO journal

External Links

Snippet

A major question in cell biology is how molecular specificity is achieved by different growth factor receptors that activate apparently identical signaling events. For the neurotrophin family, a distinguishing feature is the ability to maintain a prolonged duration of signal …
Continue reading at www.embopress.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Similar Documents

Publication Publication Date Title
Arévalo et al. A unique pathway for sustained neurotrophin signaling through an ankyrin‐rich membrane‐spanning protein
Qian et al. Identification and characterization of novel substrates of Trk receptors in developing neurons
Tanaka et al. Tiam1 mediates neurite outgrowth induced by ephrin‐B1 and EphA2
Holland et al. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells
Arévalo et al. Cell survival through Trk neurotrophin receptors is differentially regulated by ubiquitination
Persaud et al. Nedd4‐1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function
Burton et al. Abl tyrosine kinases are required for infection by Shigella flexneri
Mainiero et al. The coupling of α6β4 integrin to Ras–MAP kinase pathways mediated by Shc controls keratinocyte proliferation
Deinhardt et al. Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac
Bowlby et al. Modulation of the Kv1. 3 potassium channel by receptor tyrosine kinases
Dikic et al. Shc Binding to Nerve Growth Factor Receptor Is Mediated by the Phosphotyrosine Interaction Domain (∗)
Kobayashi et al. MAPKAPK‐2‐mediated LIM‐kinase activation is critical for VEGF‐induced actin remodeling and cell migration
Shamah et al. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin
Yokoyama et al. BANK regulates BCR‐induced calcium mobilization by promoting tyrosine phosphorylation of IP3 receptor
Tsai et al. The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity
Zwartkruis et al. Extracellular signal‐regulated activation of Rap1 fails to interfere in Ras effector signalling
Takasu et al. Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors
Mason et al. Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation
Boute et al. Dynamics of the interaction between the insulin receptor and protein tyrosine‐phosphatase 1B in living cells
Sonnleitner et al. Functional properties of the ryanodine receptor type 3 (RyR3) Ca2+ release channel
Vilar et al. Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle
Anastasi et al. Feedback inhibition by RALT controls signal output by the ErbB network
Martinez et al. Dual regulation of neuronal morphogenesis by a δ-catenin–cortactin complex and Rho
Tsai et al. Receptor protein tyrosine phosphatase α participates in the m1 muscarinic acetylcholine receptor‐dependent regulation of Kv1. 2 channel activity
Haglund et al. Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation